-
Featured
Treatments for Benign Prostatic Hyperplasia
Current treatments generally focus on oral medications or invasive surgery, which can have side effects. The prostatic urethral lift and water steam therapy are effective, non-invasive treatments for BPH.
-
Featured
Multiparametric MRI/Ultrasound Fusion Biopsy Improves Prostate Cancer Detection
Active surveillance (AS) has become an accepted way to manage prostate cancer in men at lower risk. Multiparametric MRI can be used in conjunction with the standard transrectal ultrasound (TRUS)-guided biopsy to improve detection of clinically significant cancers.
-
Featured
BPH Supplements Have Little Support for Efficacy and Safety
To better advise patients about herbal remedies for prostate enlargement or benign prostatic hyperplasia (BPH), researchers scoured the scientific literature for evidence on every individual ingredient of every available supplement.
-
Prostate Cancer Patients with Posterior Positive Surgical Margins Have Poorer Prognosis
Shulin Wu, MD, PhD, and Chin-Lee Wu, MD, PhD, of the Departments of Urology and Pathology, present evidence that prostate cancer patients who have posterior positive surgical margins (PSM) after radical prostatectomy have a more aggressive disease than those with anterior PSM.
-
Photoselective Vaporization of the Prostate Is Similar to Transurethral Resection
Real-world evidence shows no differences in treatment failure between photoselective vaporization and transurethral resection of the prostate, and endoscopic enucleation might be even more effective, according to Daniel M. Frendl, MD, PhD, and Michelle M. Kim, MD, PhD, and colleagues.
-
Darolutamide Delays Metastasis and Death in Patients with Nonmetastatic, Castration-Resistant Prostate Cancer
Matthew R. Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, and colleagues demonstrated in a worldwide phase 3 trial in patients with nonmetastatic, castration-resistant prostate cancer that darolutamide reduced the risk of metastasis or death from any cause by 59%.
Prostate Contributors
-
Adam Scott Feldman, MD, MPH
Director, Combined Harvard Urologic Oncology Fellowship, Urologic Oncologist, Department of Urology, Faculty, The Carol and James Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital
Recent Article
Considerations in Selecting Patients for Trimodal Therapy for Muscle-invasive Bladder Cancer
-
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Associate Professor, Harvard Medical School
Recent Article
Prostate Cancer and Translational Research
-
-
Jason A. Efstathiou, MD, DPhil
Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic
Recent Article
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy -
Matthew F. Wszolek, MD
Assistant in Urology, Massachusetts General Hospital, Instructor in Surgery, Harvard Medical School
Recent Article
Long-term Safety Profile of Salvage Cystectomy After Trimodality Therapy Seems Acceptable
-
Mukesh G. Harisinghani, MD
Director, Abdominal MRI, Department of Radiology, Massachusetts General Hospital
Recent Article
Multiparametric MRI For Prostate Cancer
-
Shahin Tabatabaei, MD
Director, Prostate Health Program
Recent Article
BPH Supplements Have Little Support for Efficacy and Safety
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.Resource Links
